Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 8/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.50 |
| ▸ | MPC2 | O95563 | 2/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7455356 | 0.89 | PTPN1 (0.63) | PTPN1CA2ALDH1A1NPSR1PPARG | |
| SCHEMBL8182679 | 0.85 | PTPN1 (0.79) | PTPN1CA2ALDH1A1NPSR1PPARG | |
| SCHEMBL13846691 | 0.85 | PTPN1 (0.67) | PTPN1CA2ALDH1A1NPSR1PPARG | |
| SCHEMBL14262660 | 0.83 | PTPN1 (0.68) | PTPN1CA2ALDH1A1NPSR1PPARG | |
| SCHEMBL6232223 | 0.83 | PTPN1 (0.61) | PTPN1CA2ALDH1A1NPSR1PPARG | |
| SCHEMBL13524845 | 0.82 | PTPN1 (0.55) | PTPN1CA2ALDH1A1NPSR1PPARG | |
| SCHEMBL6233368 | 0.82 | PTPN1 (0.67) | PTPN1CA2ALDH1A1NPSR1PPARG | |
| SCHEMBL7467226 | 0.82 | MAPT (0.55) | PTPN1ALDH1A1NPSR1PPARGMAOA | |
| SCHEMBL8181256 | 0.82 | MAPT (0.55) | PTPN1ALDH1A1NPSR1PPARGMAOA | |
| SCHEMBL13847876 | 0.81 | PTPN1 (0.54) | PTPN1CA2ALDH1A1NPSR1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | CHEN JAMES M | 2009-05-21 | — | — | US | disclosed |
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | CHEN JAMES M | 2009-05-21 | — | — | US | disclosed |
| US-7407965-B2 | Phosphonate analogs for treating metabolic diseases | GILEAD SCIENCES, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-7407965-B2 | Phosphonate analogs for treating metabolic diseases | GILEAD SCIENCES, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1253145-B1 | ALKALI METAL SALT OF THIAZOLIDINE-2,4-DIONE DERIVATIVES | KYORIN SEIYAKU KK (JP) | 2006-09-20 | — | — | EP | disclosed |
| CN-1206224-C | Substituted benzylthiazolidine-2,4-dione derivatives | KYORIN SEIYAKU KK (JP) | 2005-06-15 | — | — | CN | disclosed |
| EP-1207157-B1 | SUBSTITUTED BENZYLTHIAZOLIDINE-2,4-DIONE DERIVATIVES | KYORIN SEIYAKU KK (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1207158-B1 | SUBSTITUTED BENZYLTHIAZOLIDINE-2,4-DIONE DERIVATIVES | KYORIN SEIYAKU KK (JP) | 2005-05-25 | — | — | EP | disclosed |
| EP-1207156-B1 | SUBSTITUTED BENZYLTHIAZOLIDINE-2,4-DIONE DERIVATIVES | KYORIN SEIYAKU KK (JP) | 2005-05-18 | — | — | EP | disclosed |
| US-6818776-B2 | ANTIDIABETIC AGENTS; ANTILIPEMIC AGENTS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2004-11-16 | — | — | US | disclosed |
| US-20030101925-A1 | Novel stable crystal of thiazolidinedione derivative and process for producing the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | US | disclosed |
| US-6545026-B1 | Increase the transactivation of receptor as a ligand of human peroxisome proliferator-activated receptor and exhibit blood glucose-decreasing action and lipid-decreasing action | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2003-04-08 | — | — | US | disclosed |
| EP-1277745-A1 | NOVEL STABLE CRYSTAL OF THIAZOLIDINEDIONE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-20030013749-A1 | Alkali metal salt of thiazolidine-2,4-dione derivative | KYORIN PHARMACEUTICAL CO.,LTD. (JP) | 2003-01-16 | — | — | US | disclosed |
| CN-1382128-A | Substituted benzylthiazolidine-2,4-dione derivatives | KYORIM PHARMACEUTICAL CO LTD (JP) | 2002-11-27 | — | — | CN | disclosed |
| CN-1382130-A | Substituted benzylthiazolidine-2, 4-dione derivatives | KYORIN SEIYAKU KK (JP) | 2002-11-27 | — | — | CN | disclosed |
| EP-1253145-A1 | ALKALI METAL SALT OF THIAZOLIDINE-2,4-DIONE DERIVATIVE | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2002-10-30 | — | — | EP | disclosed |
| EP-1207157-A1 | SUBSTITUTED BENZYLTHIAZOLIDINE-2,4-DIONE DERIVATIVES | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
| EP-1207158-A1 | SUBSTITUTED BENZYLTHIAZOLIDINE-2,4-DIONE DERIVATIVES | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
| EP-1207156-A1 | SUBSTITUTED BENZYLTHIAZOLIDINE-2,4-DIONE DERIVATIVES | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013749-A1 | Alkali metal salt of thiazolidine-2,4-dione derivative | KLF5, KCNK17, ZNF787 | PTPN1 3848/4885CA2 128/4885ALDH1A1 2154/4885 |
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | PHOSPHO1, G6PC1, PC | PTPN1 1271/4885CA2 2638/4885ALDH1A1 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.